Cantor Fitzgerald Sticks to Its Buy Rating for Septerna, Inc. (SEPN) - The Globe and Mail
3 days ago • Google News
Septerna, Inc. Common Stock (SEPN)
US$ 00%
Price Chart
Key Statistics
Market Cap
$ 444.25M
P/E Ratio
0.00
Revenue (TTM)
$ 977K
Volume
0
52W High
$ 28.99
52W Low
$ 4.17
Dividend Yield
0.00%
Beta
0.00
Technicals
50-Day MA
6.5483
200-Day MA
14.2869
52 Week High
28.99
52 Week Low
4.17
About SEPN
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflamm.
Employees
75
Headquarters
South San Francisco, CA
CEO
Dr. Jeffrey T. Finer M.D., Ph.D.